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Purpose:  Recent  studies  showed  that  immunological  mechanisms  were  involved  in  the  pathogenesis  of  diabetic
retinopathy (DR). T-helper (Th) cells play an important role in chronic inflammatory disorders and autoimmune diseases.
Whether Th cells participate in the pathogenesis of DR remains unclear.
Methods:  To  evaluate  the  role  of  Th  cells  in  the  pathogenesis  of  type  2  diabetes  mellitus  with  retinopathy,  the
concentrations of interferon (IFN)-γ, interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 p70, IL-13, IL-17A,
IL-22, and tumor necrosis factor (TNF)-α in the serum of 29 patients with type 2 diabetes mellitus and 30 normal controls
were measured with FlowCytomix Technology. IL-22 levels in unstimulated and stimulated peripheral blood mononuclear
cells (PBMCs) were examined with enzyme-linked immunosorbent assay.
Results: We found that the mean IL-22 serum levels were slightly lower in diabetic patients than in normal controls. The
IL-22 level of PBMCs was significantly elevated in patients with proliferative diabetic retinopathy compared with the
level in patients with non-proliferative diabetic retinopathy, patients with non-DR, and healthy controls. Additionally, the
IL-22 serum and PBMC levels were positively correlated with the duration of diabetes. Serum levels of other associated
cytokines showed no significant change in diabetic patients compared to controls.
Conclusions: These results indicate a possible role of Th22 cells in DR, and IL-22 may be involved more in the
pathogenesis of proliferative diabetic retinopathy than in other stages of DR.
Diabetic retinopathy (DR) is a common and progressive
complication of diabetes mellitus. DR is characterized by the
loss of pericytes, hypertrophy of the basement membrane,
microaneurysm formation, increased vascular permeability,
capillary  occlusions,  neovascularization,  and  fibrovascular
proliferation [1]. The etiology and pathogenetic mechanisms
of  DR  have  not  been  clearly  elucidated.  Recently,
immunological mechanisms have been shown to be involved
in the pathogenesis of DR [2-4]. According to current data,
such as the finding of antipericyte and antiendothelial cell
autoantibodies in the circulation of diabetic patients, DR could
be  considered  an  autoimmune  disease  [5].  Additional
evidence  has  implicated  autoimmune  mechanisms  in  the
proliferative  stage  of  this  disease.  For  example,  elevated
levels of tumor necrosis factor (TNF)-α, interleukin (IL)-8,
and soluble IL-2 receptors were found in the serum of diabetic
patients [6]; increased vitreous concentrations of IL-6 and
IL-8 were also found in patients with proliferative retinopathy
[7].
CD4+ T cells are believed to play an important role in the
initiation of immune responses. Recent studies have shown
that among the T-helper cells, not only Th1/Th2 but also Th17,
Th9,  and  Th22  cells  contribute  to  the  pathogenesis  of
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autoimmune diseases. Each subset produces different effector
cytokines and attracts different secondary cells into the target
organ  to  induce  tissue  inflammation.  Th1  cells,  which
predominantly secrete IFN-γ, are thought to play a pathogenic
role  in  organ-specific  autoimmune  and  other  chronic
inflammatory  disorders  [8,9].  Th2  cells,  which  primarily
produce  IL-4,  IL-5,  and  IL-13,  strongly  inhibit  Th1
differentiation and are responsible for the pathogenesis of
allergic diseases [10]. Recently, the identification and cloning
of  new  cytokines  have  expanded  the  series  of  functional
subsets of CD4+ Th cells. Rather than Th1 cells, CD4+ Th cells
that  produce  IL-17,  denoted  as  Th17  cells,  have  been
implicated in the pathogenesis of many chronic inflammatory
disorders [11,12]. Moreover, another two subsets of effector
CD4+ Th cells, denoted as Th9 and Th22 cells, have been
described, although their pathological and physiologic roles
are still unclear [13-16].
To establish whether Th cells play an important role in
the pathogenesis of DR, we investigated the serum levels of
Th-associated  cytokines  in  patients  with  type  2  diabetes
mellitus  (T2DM)  with  retinopathy  compared  with  normal
controls, and then further investigated the related cytokine
level  in  PBMCs.  Moreover,  the  correlations  of  several
cytokines with disease severity were determined.
METHODS
Study population: Diabetes was diagnosed according to the
1999  World  Health  Organization  criteria  [17].  DR  was
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219assessed with fluorescein fundus angiography examination
(Zeiss FF450, Jena, Germany). DR was classified according
to the new international classification standard for diabetic
retinopathy [18]. In the diabetes group, nine had non-DR
(NDR),  ten  had  non-proliferative  diabetic  retinopathy
(NPDR), and ten had proliferative diabetic retinopathy (PDR).
The exclusion criteria included acute myocardial infarction,
organ  failure,  liver  disease,  stroke,  systemic  and  recent
infection,  previous  intraocular  surgery,  earlier  intravitreal
therapies,  photocoagulation  in  the  preceding  3  months,
uveitis, trauma, vitreous hemorrhage, and retinal detachment.
We also excluded patients who had taken immunosuppressive
drugs. Informed consent was obtained from all patients and
controls before entering the study. Research was performed
in accordance with the ethical standards of the Declaration of
Helsinki and the internal Ethics Committees of Sun Yat-sen
University, Guangzhou, China, which approved all of the
protocols.
Gender and age breakdown: Patients were recruited from the
Department of Ophthalmology of the Zhongshan Ophthalmic
Figure 1. Interleukin (IL)-22 levels in the serum from type 2 diabetes
mellitus (T2DM) patients (n=29) and healthy control subjects (n=30)
were  measured  by  FlowCytomix.  Student's  t-test  showed  that
concentrations of IL-22 in serum were significantly lower in patients
with T2DM than in healthy control subjects (p=0.007).
Center. All patients with T2DM were receiving appropriate
diet  and  glucose-lowering  medicationat  the  time  of
recruitment such as insulin, oral hypoglycemic agents, the
insulin-sensitizer agent metformin, alone or in combination
(insulin treatment [n=9, 31.03%], oral hypoglycemic agents
[n=11, 37.93%], metformin [n=20, 68.97%]. We obtained
age- and sex-matched samples from 29 T2DM patients and 30
healthy subjects. The mean age of the diabetic subjects (12
men and 17 women) was 55.0 years (SD±10.4 years, range
from 31 to 76 years). The mean age of the healthy control
subjects (16 men and 14 women) was 57.6 years (SD± 8.3
years, range from 43 to 69 years). Of the 29 T2DM patients,
there  were  nine  patients  without  DR  (mean  age±SD,
52.4±13.0 years), ten patients with NPDR (58.4±11.4 years),
and  ten  patients  with  PDR  (54.2±5.1  years).  The  mean
hemoglobin  A1c  (HbA1c)  of  the  diabetic  subjects  was
Figure 2. Distribution of serum interleukin (IL)-22 concentrations in
controls  (n=30),  non-diabetic  retinopathy  (NDR,  n=9),  non-
proliferative diabetic retinopathy (NPDR, n=10) and proliferative
diabetic retinopathy (PDR, n=10) were measured by FlowCytomix.
One-way ANOVA with a post-hoc Scheffe test showed that the
serum level of IL-22 was significantly lower in NPDR compared with
the controls (p=0.023). No significant difference was found among
NDR, NPDR, and PDR groups.
TABLE 1. CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF TYPE 2 DIABETIC PATIENTS AND HEALTHY CONTROL SUBJECTS.
Parameters PDR (n=10) NPDR (n=10) NDR (n=9) Control (n=30) p
Sex (m/f) 4/6 2/8                             5/4                            16/14                     0.278
Age (years) 54.2±5.1 58.4±11.4 52.4±13.0 57.6±8.3 0.363
BMI (kg/m2) 24.13±3.43 22.9±4.17 22.32±2.13 22.92±2.21 0.536
Diabetes duration (years) 15.2±4.4 7.8±2.5 5.8±2.0 - <0.001*
FPG (mmol/l) 10.28±2.22 9.34±1.93 7.8±0.85 - 0.014*
HbAlc (%) 8.41±0.93 7.94±1.07 7.27±0.76 - 0.035*
        DR: type 2 diabetic patients with retinopathy; NDR: type 2 diabetic patients without retinopathy; NPDR: non-proliferative
        retinopathy; PDR: proliferative diabetic retinopathy; BMI, Body mass index; FPG: fasting plasma glucose; HbA1c, glycated
        hemoglobin Data are expressed as mean±SD * p≤0.05.
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2207.87±1.01% compared to 5.29±0.50% in the control subjects
(normal range HbA1c: 4.27%–6.07%; p<0.05).
Serum: Five milliliters of whole-blood samples were collected
from the patients and healthy controls’ first visit, using a
standard venipuncture technique between 9:00 and 11:00 AM
and were thawed at room temperature. Serum samples were
obtained after centrifugation at 800× g for 10 min, aliquoted,
and stored at –80 °C until assayed. The concentrations of IFN-
γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 p70, IL-13,
IL-17A, IL-22, and TNF-α in the sera were determined with
specific FlowCytomix kits.
Cell isolation and culture: The PBMCs were prepared from
heparinized  blood  with  Ficoll-Hypaque  density-gradient
centrifugation. To study the production of related cytokines
selected with Multiplex bead analysis of serum, PBMCs were
stimulated with phytohaemagglutinin (PHA) at a density of
2×106 cells/ml for 48 h and subsequently used for analysis
with enzyme-linked immunosorbent assay (ELISA).
Immunoassays to quantify cytokines with FlowCytomix kits:
The sera were assayed to determine the concentrations of
secreted  cytokines  with  FlowCytomix  kits  (Bender
MedSystems,  Vienna,  Austria)  according  to  the
manufacturer’s  instructions.  These  kits  allowed  the
simultaneous quantification of 13 cytokines, including Th1
cytokines (IFN-γ, IL-2, and TNF-α), Th2 cytokines (IL-10,
IL-4,  IL-5,  IL-6  and  IL-13),  Th17  cytokines  (IL-17  and
IL-23), Th9 cytokines (IL-9), and Th22 cytokines (IL-12,
IL-22).  In  brief,  FlowCytomix  technology  is  based  on
spectrally discrete microspheres used as the solid phase in an
immunoassay. The beads are internally dyed with Starfire
Red,  a  far-red  (685-  to  690-nm)-emitting  fluorochrome
excited by ultraviolet, argon, or helium–neon lasers. The test
samples were analyzed with flow cytometry using Coulter
Epics FC500 (Beckman Coulter, Inc., Fullerton, CA). For
each analysis, up to 10,000 events were acquired. The mean
concentration of each cytokine was expressed as pg/ml. Using
these kits, the minimum detectable concentrations of IFN-γ,
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 p70, IL-13,
IL-17A, IL-22, and TNF-α were 1.6 pg/ml, 4.2 pg/ml, 16.4
pg/ml, 20.8 pg/ml, 1.6 pg/ml, 1.2 pg/ml, 1.5 pg/ml, 1.9 pg/ml,
1.5 pg/ml, 4.5 pg/ml, 2.5 pg/ml, and 43.3 pg/ml, respectively.
Enzyme-linked immunosorbent assay for IL-22 in peripheral
blood mononuclear cells: The protein levels of IL-22 in the
collected  supernatants  were  measured  by  using  a  Duoset
ELISA development kit (R&D Systems, Minneapolis, MN).
The  minimal  detectable  concentration  was  20  pg/ml.  All
samples were measured in duplicate.
Statistical analysis: Data were analyzed using the statistical
package  for  social  sciences  (SPSS  Version  19.0  for
Windows).  Group  differences  between  samples  from
diabetics and controls were analyzed using the two-tailed
Student t test or two-tailed Mann–Whitney test depending on
normality assumptions and the homogeneity of variances. The
differences in biochemical parameters among the groups with
different degrees of DR severity were evaluated with one-way
ANOVA with a post-hoc Scheffe test. Graphs were prepared
with Prism version 5 (GraphPad Software Inc., La Jolla, CA).
For  all  tests,  p  values  less  than  0.05  were  considered
significantly different.
RESULTS
Patients’ clinical characteristics: The clinical characteristics
of the enrolled patients are shown in Table 1. With regard to
age,  sex,  and  body  mass  index  (BMI)  distribution,  no
significant difference was observed between the study groups
(p=0.363,  p=0.232,  p=0.536,  respectively).  The  mean
duration of diabetes was significantly longer in the PDR group
than in the NPDR and NDR groups (p<0.01), although no
significant difference was found between the NPDR and NDR
groups (p=0.509).
TABLE 2. IL-1Β, IL-2, IL-5, IL-6, IL-10, IL-13, IL-17A, IL-22, TNF-Α IN THE SERUM SAMPLES OF T2DM AND CONTROL
PATIENTS (PG/ML).
Cytokines studied T2DM (n=29) Control subjects (n=30) p
IL-1β 3.82±3.0 8.35±6.20 0.113
IL-2 17.10±13.08 13.12±10.45 0.636
IL-5 8.01±5.3 6.45±3.10 0.361
IL-6 16.99±33.93 25.27±21.29 0.442
IL-9 4.4 3.47±0.64 0.185
IL-10 2.68±2.23 3.08±1.91 0.603
IL-13 12.32 19.79±4.86 0.263
IL-17A 3.37±2.0 3.59±0.33 0.836
IL-22 464.51±80.62 536.16±114.26 0.007*
TNF-α 28.88±29.85 38.56±51.26 0.508
        Controls: healthy subjects; T2DM: type 2 diabetes mellitus patients; IL, interleukin; TNF: tumor necrosis factor Data are
        expressed as mean±SD * p≤0.05.
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221HbA1c  values  between  4.27%  and  6.07%  were
considered  normal  in  our  laboratory.  HbA1c  and  fasting
glucose levels were also found to differ significantly between
the NDR and PDR groups (p<0.001, p=0.003, respectively).
Expression profiles of cytokines in the serum: After adjusting
for age, sex, and BMI, we observed that the IL-22 serum level
was significantly decreased in the diabetic group compared to
the controls (p=0.007) (Figure 1). However, the concentration
of IL-22 in serum was not significantly different among the
NDR, NPDR, and PDR groups (Figure 2). The mean serum
levels of IL-1β, IL-2, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A,
and TNF-α demonstrated no significant difference in patients
compared to the controls (Table 2). IFN-γ and IL-12 serum
levels were below the detection limits. The serum levels of all
investigated parameters did not correlate with the DR stage
(p>0.05).
Concentrations  of  IL-22  in  the  supernatants  of  cultured
peripheral blood mononuclear cells: The results showed that
significantly higher expression was noted in patients with
PDR (n=10) than in patients with NPDR (n=10; p<0.001) and
NDR  (n=9;  p=0.034).  Following  PHA  stimulation,  IL-22
production  was  significantly  increased,  with  a  higher
upregulation in patients with PDR than in patients with NPDR
(p=0.001), patients with NDR (p=0.006), and normal control
subjects (n=10, p=0.035) (Table 3, Figure 3).
Correlation  analyses  in  diabetic  retinopathy:  Correlation
analysis showed that IL-22 concentrations in serum (r=0.479,
p=0.009), unstimulated (r=0.672, p<0.001) and stimulated
Figure 3. Interleukin (IL)-22 in the supernatants of peripheral blood
mononuclear cells (PBMCs) from NDR (n=9), NPDR (n=10), PDR
(n=10) and normal control subjects (n=10) were measured by ELISA.
Separated  PBMCs  were  cultured  with  or  without
Phytohaemagglutinin (PHA, 0.02%) for 48 h. Data are represented
as  means±SD.  One-way  ANOVA  with  a  post-hoc  Scheffe  test
demonstrated a significantly higher expression in patients with PDR
than in patients with NPDR (p<0.001) and NDR (p=0.034). IL-22
production was significantly increased after PHA stimulation, with
a higher upregulation in patients with PDR than in patients with
NPDR (p=0.001), NDR (p=0.006) and control subjects (p=0.035).
TABLE 3. CONCENTRATIONS OF IL-22 IN CULTURE SUPERNATANTS OF UNSTIMULATED OR ACTIVATED PBMCS FROM TYPE 2 DIABETES MELLITUS AND HEALTHY
CONTROLS.
Cytokine PBMCs Control subjects
(n=10)
NDR (n=9) NPDR (n=10) PDR (n=10) p
IL-22 (unstimulated) 411.25±85.16 389.69±52.73 305.36± 89.73 513.08±119.97 <0.001
  (stimulated) 528.73± 463.64 440.50±89.47 377.01± 138.32 871.72±153.00 0.001
         NDR, non diabetic retinopathy; DR, diabetic retinopathy; IL, interleukin; IFN-γ, interferon-gamma, PBMCs, peripheral blood
         mononuclear cells. All cytokines expressed as pg/ml. Data are means±SD.
TABLE 4. CORRELATION BETWEEN IL-22 AND AGE, GENDER, BMI, DURATION OF DIABETES AND HBA1C LEVELS IN T2DM.
Variables Serum Unstimulated PBMCs Stimulated PBMCs
  Coefficient p Coefficient p Coefficient p
Age −0.25 0.191 −0.157 0.341 0.149 0.366
Gender 0.129 0.504 −0.166 0.311 0.212 0.194
BMI 0.356 0.058 0.155 0.346 0.072 0.663
Duration of T2DM 0.479 0.009* 0.672 <0.001* 0.68 <0.001*
FPG 0.197 0.305 0.078 0.686 0.122 0.529
HbAlc 0.061 0.754 0.279 0.143 0.256 0.18
         T2DM, type 2 diabetes mellitus; BMI, Body mass index; FPG: fasting plasma glucose; HbA1c, glycated hemoglobin; IL,
         interleukin. The coefficients were calculated from the Pearson correlation test * p≤0.05.
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222PBMCs (r=0.680, p<0.001) were positively correlated with
the duration of diabetes (Table 4, Figure 4, Figure 5, and
Figure 6). No other significant correlations were found among
the  cytokine  levels  analyzed.  No  correlation  was
demonstrated  between  serum  cytokine  concentrations  and
HbA1c or fasting plasma glucose (FPG) levels.
DISCUSSION
Th cells play a critical role in the pathogenesis of chronic
inflammation  disease.  However,  whether  this  mechanism
happens in patients with diabetes is currently unknown. Th22
is a new subset of T cells clearly distinct from Th17, with
distinct gene expression and function. IL-22 is expressed by
Th22 and highly upregulated during chronic inflammatory
diseases [19,20]. The present study indicated that IL-22 was
slightly decreased in the T2DM serum. However, is this small
decrease of clinical relevance?
IL-22, a member of the IL-10 family of cytokines, is
produced  by  special  immune  cell  populations,  including
Th22, Th1, and Th17 cells. Additionally, IL-22 has been most
commonly considered a proinflammatory cytokine due to its
expression  in  the  lesions  of  patients  with  chronic
inflammatory diseases, such as rheumatoid arthritis, Crohn’s
disease, psoriasis, and atopic dermatitis by inducing other
proinflammatory cytokines, such as IL-6, IL-8, and TNF-α
[21].  However,  IL-22  has  also  shown  a  less  direct
inflammatory role and instead induced the expression of genes
associated  with  antimicrobial  defense  and  cellular
differentiation  [22,23].  Previous  studies  have  shown
decreased serum and plasma levels of IL-22 in patients with
sarcoidosis  and  systemic  lupus  erythematosus  [24-26].
Moreover,  Sugimoto  et  al.  [27]  reported  that  IL-22
ameliorated  intestinal  inflammation  in  a  mouse  model  of
ulcerative colitis. Evidence has shown that IL-22 contributed
Figure  4.  Correlation  analysis  showed  that  interleukin  (IL)-22
concentrations in serum were positively correlated with the duration
of diabetes(r=0.479, p=0.009). Pearson’s correlation test was used
(p<0.05 significance; r=correlation coefficient).
to regulating hepatitis and is protective in inflammatory bowel
disease [28,29]. The cause of this IL-22 disparity remains
elusive. It could be explained by the theory that IL-22 plays a
dual role in inflammation depending on the specific tissue
[27]. Apart from IL-22’s dual role in autoimmune disease,
what degree of under-expression of IL-22 is detrimental for
the eye is currently unknown. Hence, the small change in the
IL-22 level in serum might exert little influence on T2DM.
In addition, the serum concentrations of cytokines are
influenced by many factors, and several types of cells could
produce cytokines. Thus, we further specifically used PBMC
cultures to evaluate IL-22 levels in patients and controls. Our
results  demonstrated  that  the  levels  of  IL-22  were
significantly increased in the PBMCs of patients with PDR
compared with the PBMCs of patients with NPDR, patients
with NDR, and healthy controls, implying that Th22 may be
involved in the pathogenesis of PDR.
PDR  is  the  advanced  stage  of  DR  characterized  by
uncontrolled  vascular  proliferation  leading  to  fibrosis  and
traction retinal detachments [30]. As in many fibrotic eye
diseases such as age-related macular degeneration, an injury
to  the  retina  could  result  in  inflammatory  changes,  tissue
edema,  and  hypoxia-driven  neovascularization  prone  to
hemorrhage,  leading  to  further  activation  of  the  wound-
healing  response,  and  ultimately  development  of  severe
fibrosis  [31].  In  addition  to  inflammation  induced  by
autoimmune or infectious diseases, IL-22 also plays a role in
fibrosis  after  wounding.  IL-22  is  highly  expressed  in
rheumatoid arthritis (RA), in which IL-22 induces production
of monocyte chemoattractant protein-1 (CCL2; also known as
MCP-1)  and  proliferation  of  synovial  fibroblasts  and
osteoclasts [32,33]. Raised vitreous CCL2 levels have been
reported in several studies. A possible role for CCL2 in PDR
Figure  5.  Correlation  analysis  showed  that  interleukin  (IL)-22
concentrations in unstimulated peripheral blood mononuclear cells
(PBMCs) were positively correlated with the duration of diabetes
(r=0.672,  p<0.001)  .Pearson’s  correlation  test  was  used  (p<0.05
significance; r=correlation coefficient).
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Recently,  several  fibroblast  growth  factors,  such  as
connective tissue growth factor (CTGF) levels, were found to
correlate significantly with the degree of fibrosis in various
vitreoretinal  disorders  including  proliferative
vitreoretinopathy and PDR [36,37]. Th22 cells also produce
fibroblast growth factors [38]. Therefore, Th22 cells may be
involved  in  the  pathogenesis  of  PDR  by  regulating
angiogenesis and fibrosis. On the other hand, IL-22 has minor
proinflammatory effects, and in some cases such as uveitis,
IL-22 seems to play an aggravating role in the pathogenesis
of autoimmune disease. IL-22 is expressed in uveitis, in which
IL-22 decreases total tissue resistance and induces apoptosis
in  retinal  pigment  epithelial  cells  [39].  Therefore,  we
speculate that the Th22 cells of peripheral blood may reach
the eye and play some pathophysiologic role in this way.
Because  IL-22  exhibits  potent  angiogenic  or  angiostatic
activity, targeting IL-22 might offer a unique approach to
regulate  angiogenesis  and  fibrosis.  However,  the  clinical
association  between  Th22  cells  and  PDR  remains  to  be
elucidated.
Another interesting finding in this study was that IL-22
exhibited a positive correlation with the duration of diabetes.
However, the duration of diabetes may not accurately reflect
a  patient’s  true  history  because  diabetes  can  often  go
undetected for several years. No association of serum IL-22
levels with the severities of DR was found in our study, which
may  be  explained  by  the  relatively  small  sample  size.
Therefore, prospective cohort studies with larger sample sizes
are needed.
In our analyses of serum cytokine profiles, no cytokine
differed significantly between T2DM patients and controls,
except  IL-22,  whereas  levels  of  these  cytokines  were
Figure  6.  Correlation  analysis  showed  that  interleukin  (IL)-22
concentrations  in  stimulated  peripheral  blood  mononuclear  cells
(PBMCs)  were  positively  correlated  with  the  duration  of
diabetes(r=0.680,  p<0.001).  Pearson’s  correlation  test  was  used
(p<0.05 significance; r=correlation coefficient).
increased or undetectable in patients with type 2 diabetes.
Various investigators have detected elevated levels of IL-6 in
ocular  fluid  from  patients  with  diabetic  retinopathy  [40].
Serum concentrations of TNF-α were reported to be elevated
in diabetic patients [41]. Moreover, in a recent study, non-
inflammatory  cytokines,  such  as  IL-2,  IL-4,  IL-10,  and  a
major proinflammatory cytokine (IFN-γ) were not detected in
vitreous  fluid  in  patients  with  diabetic  retinopathy  [42].
Therefore, to clarify the role of Th cells in T2DM patients with
retinopathy, further studies on multiple potential origins, such
as peripheral blood mononuclear cells or vitreous fluid, are
required.
In conclusion, an increase in IL-22 levels in patients with
PDR  suggests  that  IL-22  may  be  associated  with  the
pathogenetic  mechanism  of  this  disease  and  could  be  an
important target for developing new drugs and treatments for
PDR.
ACKNOWLEDGMENTS
This study was supported by the National Basic Research
Program of China (grant number: 2007CB512206) and the
National Natural Science Foundation of China (grant number:
81070745).  The  authors  have  no  financial  or  conflicting
interests to disclose.
REFERENCES
1. Davis MD. Diabetic retinopathy. A clinical overview. Diabetes
Care 1992; 15:1844-74. [PMID: 1464242]
2. Attawia  MA,  Nayak  RC.  Circulating  antipericyte
autoantibodies  in  diabetic  retinopathy.  Retina  1999;
19:390-400. [PMID: 10546933]
3. Tang S, Le-Ruppert KC. Activated T lymphocytes in epiretinal
membranes from eyes of patients with proliferative diabetic
retinopathy.  Graefes  Arch  Clin  Exp  Ophthalmol  1995;
233:21-5. [PMID: 7721119]
4. Maier  R,  Weger  M,  Haller-Schober  EM,  El-Shabrawi  Y,
Wedrich A, Theisl A, Aigner R, Barth A, Haas A. Multiplex
bead  analysis  of  vitreous  and  serum  concentrations  of
inflammatory and proangiogenic factors in diabetic patients.
Mol Vis 2008; 14:637-43. [PMID: 18385799]
5. Nayak  RC,  Lynch  K,  Gustavsson  C,  Kwok  MG,  Farthing-
Nayak PJ, Agardh CD, Agardh E. Circulating antipericyte
autoantibodies: a novel modifier of risk of progression of
diabetic  retinopathy?  Retina  2007;  27:211-5.  [PMID:
17290204]
6. Doganay S, Evereklioglu C, Er H, Turkoz Y, Sevinc A, Mehmet
N, Savli H. Comparison of serum NO, TNF-alpha, IL-1beta,
sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in
patients  with  diabetes  mellitus.  Eye  (Lond)  2002;
16:163-70. [PMID: 11988817]
7. Yuuki  T,  Kanda  T,  Kimura  Y,  Kotajima  N,  Tamura  J,
Kobayashi I, Kishi S. Inflammatory cytokines in vitreous
fluid and serum of patients with diabetic vitreoretinopathy. J
Diabetes Complications 2001; 15:257-9. [PMID: 11522500]
8. Lohmann T, Laue S, Nietzschmann U, Kapellen TM, Lehmann
I, Schroeder S, Paschke R, Kiess W. Reduced expression of
Th1-associated  chemokine  receptors  on  peripheral  blood
Molecular Vision 2012; 18:219-226 <http://www.molvis.org/molvis/v18/a25> © 2012 Molecular Vision
224lymphocytes at diagnosis of type 1 diabetes. Diabetes 2002;
51:2474-80. [PMID: 12145160]
9. Jäger A, Kuchroo VK. Effector and regulatory T-cell subsets in
autoimmunity  and  tissue  inflammation.  Scand  J  Immunol
2010; 72:173-84. [PMID: 20696013]
10. Romagnani S. Biology of human TH1 and TH2 cells. J Clin
Immunol 1995; 15:121-9. [PMID: 7559914]
11. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B,
Lucian  L,  To  W,  Kwan  S,  Churakova  T,  Zurawski  S,
Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick
JD. Interleukin-23 rather than interleukin-12 is the critical
cytokine for autoimmune inflammation of the brain. Nature
2003; 421:744-8. [PMID: 12610626]
12. Murphy  CA,  Langrish  CL,  Chen  Y,  Blumenschein  W,
McClanahan  T,  Kastelein  RA,  Sedgwick  JD,  Cua  DJ.
Divergent  pro-  and  antiinflammatory  roles  for  IL-23  and
IL-12 in joint autoimmune inflammation. J Exp Med 2003;
198:1951-7. [PMID: 14662908]
13. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel
RA, Mitsdoerffer M, Strom TB, Elyaman W, Ho IC, Khoury
S, Oukka M, Kuchroo VK. IL-4 inhibits TGF-beta-induced
Foxp3+ T cells and, together with TGF-beta, generates IL-9+
IL-10+  Foxp3(-)  effector  T  cells.  Nat  Immunol  2008;
9:1347-55. [PMID: 18997793]
14. Veldhoen  M,  Uyttenhove  C,  van  Snick  J,  Helmby  H,
Westendorf A, Buer J, Martin B, Wilhelm C, Stockinger B.
Transforming  growth  factor-beta  'reprograms'  the
differentiation of T helper 2 cells and promotes an interleukin
9-producing subset. Nat Immunol 2008; 9:1341-6. [PMID:
18931678]
15. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F.
Production of interleukin 22 but not interleukin 17 by a subset
of human skin-homing memory T cells. Nat Immunol 2009;
10:857-63. [PMID: 19578369]
16. Trifari  S,  Kaplan  CD,  Tran  EH,  Crellin  NK,  Spits  H.
Identification of a human helper T cell population that has
abundant production of interleukin 22 and is distinct from
T(H)-17,  T(H)1  and  T(H)2  cells.  Nat  Immunol  2009;
10:864-71. [PMID: 19578368]
17. Alberti  KG,  Zimmet  PZ.  Definition,  diagnosis  and
classification of diabetes mellitus and its complications. Part
1: diagnosis and classification of diabetes mellitus provisional
report  of  a  WHO  consultation.  Diabet  Med  1998;
15:539-53. [PMID: 9686693]
18. Expert  Committee  on  the  Diagnosis  and  Classification  of
Diabetes Mellitus. Report of the expert committee on the
diagnosis and classification of diabetes mellitus. Diabetes
Care 2003; 26:S5-20. [PMID: 12502614]
19. Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y,
Tsujikawa T, Kitoh K, Kim-Mitsuyama S, Takayanagi A,
Shimizu N, Fujiyama Y. Interleukin-22, a member of the
IL-10 subfamily, induces inflammatory responses in colonic
subepithelial  myofibroblasts.  Gastroenterology  2005;
129:969-84. [PMID: 16143135]
20. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte
JM, Diepolder H, Marquardt A, Jagla W, Popp A, Leclair S,
Herrmann  K,  Seiderer  J,  Ochsenkuhn  T,  Goke  B,
Auernhammer CJ, Dambacher J. IL-22 is increased in active
Crohn's  disease  and  promotes  proinflammatory  gene
expression  and  intestinal  epithelial  cell  migration.  Am  J
Physiol  Gastrointest  Liver  Physiol  2006;  290:G827-38.
[PMID: 16537974]
21. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ,
Karow M, Flavell RA. Interleukin-22 but not interleukin-17
provides  protection  to  hepatocytes  during  acute  liver
inflammation.  Immunity  2007;  27:647-59.  [PMID:
17919941]
22. Zheng  Y,  Danilenko  DM,  Valdez  P,  Kasman  I,  Eastham-
Anderson  J,  Wu  J,  Ouyang  W.  Interleukin-22,  a  T(H)17
cytokine, mediates IL-23-induced dermal inflammation and
acanthosis. Nature 2007; 445:648-51. [PMID: 17187052]
23. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadullah
K,  Volk  HD,  Sterry  W,  Sabat  R.  IL-22  regulates  the
expression of genes responsible for antimicrobial defense,
cellular  differentiation,  and  mobility  in  keratinocytes:  a
potential  role  in  psoriasis.  Eur  J  Immunol  2006;
36:1309-23. [PMID: 16619290]
24. Whittington HA, Armstrong L, Uppington KM, Millar AB.
Interleukin-22: a potential immunomodulatory molecule in
the lung. Am J Respir Cell Mol Biol 2004; 31:220-6. [PMID:
15039135]
25. Pan HF, Zhao XF, Yuan H, Zhang WH, Li XP, Wang GH, Wu
GC, Tang XW, Li WX, Li LH, Feng JB, Hu CS, Ye DQ.
Decreased serum IL-22 levels in patients with systemic lupus
erythematosus. Clin Chim Acta 2009; 401:179-80. [PMID:
19046958]
26. Cheng F, Guo Z, Xu H, Yan D, Li Q. Decreased plasma IL22
levels, but not increased IL17 and IL23 levels, correlate with
disease  activity  in  patients  with  systemic  lupus
erythematosus.  Ann  Rheum  Dis  2009;  68:604-6.  [PMID:
19286907]
27. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A,
Bhan AK, Blumberg RS, Xavier RJ, Mizoguchi A. IL-22
ameliorates  intestinal  inflammation  in  a  mouse  model  of
ulcerative colitis. J Clin Invest 2008; 118:534-44. [PMID:
18172556]
28. Radaeva S, Sun R, Pan HN, Hong F, Gao B. Interleukin 22
(IL-22) plays a protective role in T cell-mediated murine
hepatitis: IL-22 is a survival factor for hepatocytes via STAT3
activation. Hepatology 2004; 39:1332-42. [PMID: 15122762]
29. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schaffer AA,
Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D,
Hatscher  N,  Pfeifer  D,  Sykora  KW,  Sauer  M,  Kreipe  H,
Lacher M, Nustede R, Woellner C, Baumann U, Salzer U,
Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S,
Snapper SB, Grimbacher B, Klein C. Inflammatory bowel
disease and mutations affecting the interleukin-10 receptor.
N Engl J Med 2009; 361:2033-45. [PMID: 19890111]
30. Wilkinson-Berka JL. Angiotensin and diabetic retinopathy. Int
J Biochem Cell Biol 2006; 38:752-65. [PMID: 16165393]
31. Friedlander M. Fibrosis and diseases of the eye. J Clin Invest
2007; 117:576-86. [PMID: 17332885]
32. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K,
Ueki  K,  Nojima  Y.  Expression  of  interleukin-22  in
rheumatoid  arthritis:  potential  role  as  a  proinflammatory
cytokine.  Arthritis  Rheum  2005;  52:1037-46.  [PMID:
15818686]
33. Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera
T, Renauld JC, Matthys P. Proinflammatory role of the Th17
cytokine  interleukin-22  in  collagen-induced  arthritis  in
Molecular Vision 2012; 18:219-226 <http://www.molvis.org/molvis/v18/a25> © 2012 Molecular Vision
225C57BL/6  mice.  Arthritis  Rheum  2009;  60:390-5.  [PMID:
19180498]
34. Strieter  RM,  Gomperts  BN,  Keane  MP.  The  role  of  CXC
chemokines  in  pulmonary  fibrosis.  J  Clin  Invest  2007;
117:549-56. [PMID: 17332882]
35. Han  QH,  Hui  YN,  Du  HJ,  Zhang  WJ,  Ma  JX,  Wang  SY.
Migration  of  retinal  pigment  epithelial  cells  in  vitro
modulated by monocyte chemotactic protein-1: enhancement
and inhibition. Graefes Arch Clin Exp Ophthalmol 2001;
239:531-8. [PMID: 11521698]
36. Sivalingam A, Kenney J, Brown GC, Benson WE, Donoso L.
Basic fibroblast growth factor levels in the vitreous of patients
with  proliferative  diabetic  retinopathy.  Arch  Ophthalmol
1990; 108:869-72. [PMID: 1693499]
37. Kuiper EJ, de Smet MD, van Meurs JC, Tan HS, Tanck MW,
Oliver  N,  van  Nieuwenhoven  FA,  Goldschmeding  R,
Schlingemann RO. Association of connective tissue growth
factor with fibrosis in vitreoretinal disorders in the human eye.
Arch Ophthalmol 2006; 124:1457-62. [PMID: 17030714]
38. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta
S, Cianfarani F, Odorisio T, Traidl-Hoffmann C, Behrendt H,
Durham  SR,  Schmidt-Weber  CB,  Cavani  A.  Th22  cells
represent a distinct human T cell subset involved in epidermal
immunity and remodeling. J Clin Invest 2009; 119:3573-85.
[PMID: 19920355]
39. Sher  A,  Coffman  RL,  Hieny  S,  Scott  P,  Cheever  AW.
Interleukin 5 is required for the blood and tissue eosinophilia
but  not  granuloma  formation  induced  by  infection  with
Schistosoma  mansoni.  Proc  Natl  Acad  Sci  USA  1990;
87:61-5. [PMID: 2104985]
40. Goldberg  RB.  Cytokine  and  cytokine-like  inflammation
markers,  endothelial  dysfunction,  and  imbalanced
coagulation in development of diabetes and its complications.
J  Clin  Endocrinol  Metab  2009;  94:3171-82.  [PMID:
19509100]
41. Hussain MJ, Peakman M, Gallati H, Lo SS, Hawa M, Viberti
GC, Watkins PJ, Leslie RD, Vergani D. Elevated serum levels
of macrophage-derived cytokines precede and accompany the
onset  of  IDDM.  Diabetologia  1996;  39:60-9.  [PMID:
8720604]
42. Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida
H, Oshima Y, Ueno A, Hata Y, Yoshida H, Ishibashi T.
Comprehensive analysis of inflammatory immune mediators
in vitreoretinal diseases. PLoS ONE 2009; 4:e8158. [PMID:
19997642]
Molecular Vision 2012; 18:219-226 <http://www.molvis.org/molvis/v18/a25> © 2012 Molecular Vision
Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China.
The print version of this article was created on 25 January 2012. This reflects all typographical corrections and errata to the
article through that date. Details of any changes may be found in the online version of the article.
226